Related references
Note: Only part of the references are listed.Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015
Kelly E. Faulk et al.
PLOS ONE (2020)
Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future
Wayne H. Liang et al.
JCO CLINICAL CANCER INFORMATICS (2020)
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma A Randomized Clinical Trial
Julie R. Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
Jonathan M. Loree et al.
JAMA ONCOLOGY (2019)
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531
Clare J. Twist et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Narjust Duma et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment
Julie A. Wolfson et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2018)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2018)
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project
Mark A. Applebaum et al.
EUROPEAN JOURNAL OF CANCER (2017)
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2017)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Participation in pediatric oncology research protocols: Racial/ethnic, language and age-based disparities
Paula Aristizabal et al.
PEDIATRIC BLOOD & CANCER (2015)
Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop
Sandra E. Brooks et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials
Joseph M. Unger et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study
J. A. Kohler et al.
EUROPEAN JOURNAL OF CANCER (2013)
Does Enrollment in Cancer Trials Improve Survival?
Christopher J. Chow et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2013)
Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival
Eric R. Gamazon et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
Susan G. Kreissman et al.
LANCET ONCOLOGY (2013)
Children's Oncology Group's 2013 blueprint for research: Survivorship and outcomes
Saro H. Armenian et al.
PEDIATRIC BLOOD & CANCER (2013)
Clinical Trial Participation and Time to Treatment Among Adolescents and Young Adults With Cancer: Does Age at Diagnosis or Insurance Make a Difference?
Helen M. Parsons et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study
Tara O. Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
B. De Bernardi et al.
BRITISH JOURNAL OF CANCER (2008)
Progress in Childhood Cancer: 50 Years of Research Collaboration, a Report From the Children's Oncology Group
Mouro O'Leary et al.
SEMINARS IN ONCOLOGY (2008)
Different rates of clinical trial enrollment between adolescents and young adults aged 15 to 22 years old and children under 15 years old with cancer at a Children's Hospital
Peter H. Shaw et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy
R Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review
JM Peppercorn et al.
LANCET (2004)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
